J&J
UK Launches Public-Private iDx-Lung Consortium to Improve Early Detection of Lung Cancers
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
AnchorDx, Johnson & Johnson Collaborate on Early-Stage Lung Cancer Diagnosis Study
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Envisagenics to Bring RNA Splicing Software Platform to J&J Lung Cancer Initiative
The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.
Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
UK Biobank Whole-Genome Sequencing Project Obtains £200M from Pharma, Government, Philanthropy
The project is funded with £50 million from the UK government, £50 million from the Wellcome Trust, and £100 million from four pharmaceutical firms.